Acute tumor lysis syndrome with metastatic medulloblastoma: A case report

Tomlinson, Gregory C.; Solberg, Lawrence A.

doi:10.1002/1097-0142(19840415)53:8<1783::aid-cncr2820530829>3.0.co;2-f

Cited by 53 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…98,101 One patient was a 34 year old female, 98 and the second was a 23 year old male. 101 One patient had baseline elevation of LDH, 98 and borderline creatinine, whereas the second had elevated LDH alone. 101 One patient was treated with radiation, dexamethasone and vincristine.…”

Section: Tumor Lysis Syndrome In Patients With Neurological Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

et al. 2014

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is a potentially deadly complication of tumors or their treatment. This syndrome consists of a constellation of laboratory findings such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, known as laboratory TLS. When clinical complications such as seizures, acute renal failure, and cardiac dysrhythmias occur in patients with laboratory TLS, the syndrome is called clinical TLS. TLS is especially common in patients with hematological malignancies with rapid cellular turnover rates such as acute lymphocytic leukemia and Burkitt lymphoma, but is very rare in patients with solid tumors. Nevertheless, there are multiple reports in the literature on the occurrence of TLS in patients with solid tumors. In this review article, we summarize the current data on the occurrence of TLS in patients with solid tumors. We propose an algorithm of risk stratification and prevention of TLS in patients with solid cancers.

show abstract

Section: Tumor Lysis Syndrome In Patients With Neurological Malignanciesmentioning

confidence: 99%

“…101 One patient was treated with radiation, dexamethasone and vincristine. 98 TLS developed 4 days after receiving radiation. The second patient was treated with cisplatin and etoposide.…”

Section: Tumor Lysis Syndrome In Patients With Neurological Malignanciesmentioning

confidence: 99%

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…According to a review of the English literature of the past several decades, there are scattered cases reported [2,[6][7][8] and the mortality rate of TLS in this series is significantly higher than that documented for hematological malignancies [5]. Typically, these tumors have been bulky masses with advanced stage and therapy-sensitive disease.…”

Section: Discussionmentioning

confidence: 78%

Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma

et al. 2007

View full text Add to dashboard Cite

Tumor lysis syndrome is a set of life threatening complication that can arise from treatment of high tumor burden, drug sensitive, and rapidly proliferating neoplasm particularly of hematological origin. It is rarely described in patients with solid tumors. We report the first case of tumor lysis syndrome in a man with metastatic renal pelvic transitional cell carcinoma after gemcitabine treatment. Despite aggressive therapy, he died 2 weeks after TLS was diagnosed. Our experience demonstrates that administration of gemcitabine for metastatic renal pelvic transitional cell carcinoma may induce acute tumor lysis syndrome, which necessitates frequent laboratory monitoring and prompt initiation of appropriate therapeutic measures.

show abstract

“…According to a review of the English literature, clinically significant TLS may occur most often in patients with acute leukemia with high WBC counts and in those with high-grade lymphomas responsive to aggressive treatment [1]. However, TLS also may occur in other hematologic malignancies and in a variety of solid tumors such as prostate cancer [6], breast cancer [7], medulloblastoma [8], gastric cancer [9], and kidney transitional cell carcinoma [10]. Typically, these tumors have been bulky masses with advanced stage and therapy-sensitive disease.…”

Section: Discussionmentioning

confidence: 99%

Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma

et al. 2008

View full text Add to dashboard Cite

Acute tumor lysis syndrome (TLS) is a life-threatening complication of cancer therapy requiring prompt recognition and aggressive management. It occurs particularly in patients with lymphoproliferative disease during potent myelosuppressive therapy. To our knowledge, acute TLS in end-stage renal disease (ESRD) patients with malignancy is extremely rare and has never been reported in English literature. We report the first case of acute TLS in an ESRD woman with diffuse large B cell lymphoma after chemotherapy. Aggressive treatments with daily hemodialysis and allopurinol rather than hydration benefit the patient. There is neither optimal therapy in treating ESRD patients with TLS nor adequate guidelines for how to adjust the chemotherapy drug in hemodialysis patients. This case provides our experience to clinician how to treat acute TLS in ESRD patients.

show abstract

Acute tumor lysis syndrome with metastatic medulloblastoma: A case report

Cited by 53 publications

References 15 publications

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma

Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma

Contact Info

Product

Resources

About